{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:56:51Z","timestamp":1788184611501,"version":"build-2803163510"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01803-5","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T01:07:09Z","timestamp":1785373629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-0340","authenticated-orcid":false,"given":"Rodrigo","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-4128","authenticated-orcid":false,"given":"Talal","family":"Hilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"1","key":"1803_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood. 2006;107(1):265\u201376.","journal-title":"Blood"},{"issue":"6","key":"1803_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","volume":"122","author":"D Tan","year":"2013","unstructured":"Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, et al. Improvements in observed and relative survival in follicular grade 1\u20132 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981\u20137.","journal-title":"Blood"},{"issue":"31","key":"1803_CR3","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P, Offner F, L\u00f3pez-Guillermo A, Belada D, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37(31):2815\u201324.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1803_CR4","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1111\/bjh.19449","volume":"204","author":"CJ Milrod","year":"2024","unstructured":"Milrod CJ, Kim KW, Raker C, Ollila TA, Olszewski AJ, Pelcovits A. Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: a systematic review and meta-analysis. Br J Haematol. 2024;204(6):2237\u201341.","journal-title":"Br J Haematol"},{"issue":"7","key":"1803_CR5","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720\u201348.","journal-title":"Leukemia"},{"issue":"12","key":"1803_CR6","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835\u201349.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1803_CR7","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1182\/blood.V93.7.2202","volume":"93","author":"J Rodriguez","year":"1999","unstructured":"Rodriguez J, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, et al. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood. 1999;93(7):2202\u20137.","journal-title":"Blood"},{"key":"1803_CR8","doi-asserted-by":"crossref","unstructured":"Kurz KS, Kalmbach S, Ott M, Staiger AM, Ott G, Horn H. Follicular Lymphoma in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms-Updated Classification and New Biological Data. Cancers (Basel) 2023, 15(3).","DOI":"10.3390\/cancers15030785"},{"issue":"3","key":"1803_CR9","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","volume":"64","author":"BA Guadagnolo","year":"2006","unstructured":"Guadagnolo BA, Li S, Neuberg D, Ng A, Hua L, Silver B, et al. Long-term outcome and mortality trends in early-stage, grade 1\u20132 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006;64(3):928\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1803_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","volume":"133","author":"JL Brady","year":"2019","unstructured":"Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, et al. Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019;133(3):237\u201345.","journal-title":"Blood"},{"key":"1803_CR11","doi-asserted-by":"crossref","unstructured":"Vargo JA, Gill BS, Balasubramani GK, Beriwal S. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer 2015, 121(18):3325\u201334.","DOI":"10.1002\/cncr.29491"},{"issue":"16","key":"1803_CR12","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.25149","volume":"116","author":"TJ Pugh","year":"2010","unstructured":"Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2010;116(16):3843\u201351.","journal-title":"Cancer"},{"issue":"8","key":"1803_CR13","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.3109\/10428194.2014.990010","volume":"56","author":"A Janikova","year":"2015","unstructured":"Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Belada D, et al. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy? Leuk Lymphoma. 2015;56(8):2350\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"29","key":"1803_CR14","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","volume":"36","author":"M MacManus","year":"2018","unstructured":"MacManus M, Fisher R, Roos D, O\u2019Brien P, Macann A, Davis S, Tsang R, Christie D, McClure B, Joseph D, et al. Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. J Clin Oncol. 2018;36(29):2918\u201325.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1803_CR15","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","volume":"30","author":"P Solal-C\u00e9ligny","year":"2012","unstructured":"Solal-C\u00e9ligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848\u201353.","journal-title":"J Clin Oncol"},{"issue":"9383","key":"1803_CR16","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, Marcus RE, Jelliffe A, Vaughan G, Hudson, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516\u201322.","journal-title":"Lancet"},{"issue":"4","key":"1803_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424\u201335.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1803_CR18","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1016\/S2352-3026(25)00034-1","volume":"12","author":"M Northend","year":"2025","unstructured":"Northend M, Wilson W, Ediriwickrema K, Clifton-Hadley L, Qian W, Rana Z, et al. Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial. Lancet Haematol. 2025;12(5):e335\u201345.","journal-title":"Lancet Haematol"},{"issue":"19","key":"1803_CR19","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1200\/JCO.22.02327","volume":"41","author":"G Cartron","year":"2023","unstructured":"Cartron G, Bachy E, Tilly H, Daguindau N, Pica GM, Bijou F, et al. Randomized phase III trial evaluating subcutaneous rituximab for the first-line treatment of low-tumor burden follicular lymphoma: results of a LYSA study. J Clin Oncol. 2023;41(19):3523\u201333.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1803_CR20","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/bjh.19918","volume":"206","author":"MAV Marzolini","year":"2025","unstructured":"Marzolini MAV, Qian W, Clifton-Hadley L, Patrick P, Warden J, Stevens L, et al. Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting. Br J Haematol. 2025;206(3):876\u201386.","journal-title":"Br J Haematol"},{"issue":"22","key":"1803_CR21","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","volume":"34","author":"C Sarkozy","year":"2016","unstructured":"Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34(22):2575\u201382.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1803_CR22","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","volume":"5","author":"M Federico","year":"2018","unstructured":"Federico M, Caballero Barrig\u00f3n MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, Alonso-\u00c1lvarez S, Wondergem M, Cartron G, Lopez-Guillermo A, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 2018;5(8):e359\u201367.","journal-title":"Lancet Haematol"},{"issue":"16","key":"1803_CR23","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1182\/bloodadvances.2024013499","volume":"8","author":"JA Florindez","year":"2024","unstructured":"Florindez JA, Chihara D, Reis IM, Lossos IS, Alderuccio JP. Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population-based analysis. Blood Adv. 2024;8(16):4423\u201332.","journal-title":"Blood Adv"},{"issue":"3","key":"1803_CR24","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Ha\u00efoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997;15(3):1110\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1803_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjh.16872","volume":"191","author":"C McNamara","year":"2020","unstructured":"McNamara C, Montoto S, Eyre TA, Ardeshna K, Burton C, Illidge T, et al. The investigation and management of follicular lymphoma. Br J Haematol. 2020;191(3):363\u201381.","journal-title":"Br J Haematol"},{"issue":"9873","key":"1803_CR26","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310.","journal-title":"Lancet"},{"issue":"10","key":"1803_CR27","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934\u201347.","journal-title":"N Engl J Med"},{"issue":"7","key":"1803_CR28","doi-asserted-by":"publisher","first-page":"e919","DOI":"10.1097\/HS9.0000000000000919","volume":"7","author":"W Townsend","year":"2023","unstructured":"Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips EH, Dreyling M, Seymour JF, et al. Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. Hemasphere. 2023;7(7):e919.","journal-title":"Hemasphere"},{"issue":"7","key":"1803_CR29","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/bloodadvances.2024014840","volume":"9","author":"E Kimby","year":"2025","unstructured":"Kimby E, Sch\u00e4r S, Pirosa MC, Vanazzi A, Mey UM, Rauch D, et al. Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35\/10 trial 10-year update. Blood Adv. 2025;9(7):1712\u20139.","journal-title":"Blood Adv"},{"issue":"4","key":"1803_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1182\/blood-2018-10-879643","volume":"134","author":"E Zucca","year":"2019","unstructured":"Zucca E, Rondeau S, Vanazzi A, \u00d8stenstad B, Mey UJM, Rauch D, et al. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood. 2019;134(4):353\u201362.","journal-title":"Blood"},{"issue":"7","key":"1803_CR31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","volume":"36","author":"M Shadman","year":"2018","unstructured":"Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, et al. Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016. J Clin Oncol. 2018;36(7):697\u2013703.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1803_CR32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","volume":"36","author":"S Luminari","year":"2018","unstructured":"Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018;36(7):689\u201396.","journal-title":"J Clin Oncol"},{"issue":"9759","key":"1803_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42\u201351.","journal-title":"Lancet"},{"issue":"7","key":"1803_CR34","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1200\/JCO.21.01234","volume":"40","author":"S Luminari","year":"2022","unstructured":"Luminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C, et al. Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study. J Clin Oncol. 2022;40(7):729\u201339.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1803_CR35","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/cncr.35137","volume":"130","author":"Y Chu","year":"2024","unstructured":"Chu Y, Liu Y, Yu Z, Zhan L, Lu T, Jiang Y, et al. Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: a systematic review and network meta-analysis of randomized trials. Cancer. 2024;130(7):1072\u201382.","journal-title":"Cancer"},{"key":"1803_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2340\/1651-226X.2024.24377","volume":"63","author":"A Rajamaki","year":"2024","unstructured":"Rajamaki A, Sorigue M, Prusila REI, Kuusisto MEL, Kuitunen H, Jantunen E, et al. Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice. Acta Oncol. 2024;63:267\u201372.","journal-title":"Acta Oncol"},{"issue":"11","key":"1803_CR37","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster HS, Hiddemann W, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(11):1684\u201393.","journal-title":"Blood"},{"issue":"9","key":"1803_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood.2019000258","volume":"134","author":"CL Freeman","year":"2019","unstructured":"Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134(9):761\u20134.","journal-title":"Blood"},{"issue":"23","key":"1803_CR39","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516\u201322.","journal-title":"J Clin Oncol"},{"key":"1803_CR40","doi-asserted-by":"crossref","unstructured":"Sehn LH, H\u00fcbel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee H-P, Jim\u00e9nez-Ubieto A et al. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. Lancet 2025.","DOI":"10.1016\/S0140-6736(25)01778-7"},{"issue":"4","key":"1803_CR41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.hoc.2020.02.006","volume":"34","author":"J Okosun","year":"2020","unstructured":"Okosun J, Montoto S. Cellular therapy in follicular lymphoma: autologous stem cell transplantation, allogeneic stem cell transplantation, and chimeric antigen receptor T-cell therapy. Hematol Oncol Clin North Am. 2020;34(4):701\u201314.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"14","key":"1803_CR42","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188\u201399.","journal-title":"J Clin Oncol"},{"key":"1803_CR43","doi-asserted-by":"crossref","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo Pet al: An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Annals of Oncology 2011, 22(7):1622\u20131627.","DOI":"10.1093\/annonc\/mdq626"},{"key":"1803_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102747","author":"A Gurumurthi","year":"2024","unstructured":"Gurumurthi A, Chin CK, Feng L, Fowler NH, Strati P, Hagemeister FB, et al. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1\/2 trial. eClinicalMedicine. 2024. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102747.","journal-title":"eClinicalMedicine"},{"issue":"2","key":"1803_CR45","first-page":"439","volume":"110","author":"G Cassanello","year":"2024","unstructured":"Cassanello G, Drill E, Rivas-Delgado A, Okwali M, Isgor I, Caron PC, et al. Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience. Haematologica. 2024;110(2):439\u201347.","journal-title":"Haematologica"},{"issue":"8","key":"1803_CR46","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019;6(8):e429\u201337.","journal-title":"Lancet Haematol"},{"issue":"8","key":"1803_CR47","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081\u201393.","journal-title":"Lancet Oncol"},{"issue":"Supplement 2","key":"1803_CR48","doi-asserted-by":"publisher","first-page":"LBA-1","DOI":"10.1182\/blood-2024-212970","volume":"144","author":"LH Sehn","year":"2024","unstructured":"Sehn LH, Luminari S, Scholz CW, H\u00fcbel K, Salar A, Paneesha S, et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND). Blood. 2024;144(Supplement 2):LBA-1-LBA&#x02212;1.","journal-title":"Blood"},{"key":"1803_CR49","unstructured":"Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R et al. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. The Lancet."},{"issue":"1","key":"1803_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82841-w","volume":"11","author":"C Luo","year":"2021","unstructured":"Luo C, Wu G, Huang X, Ma Y, Zhang Y, Song Q, et al. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis. Sci Rep. 2021;11(1):3255.","journal-title":"Sci Rep"},{"issue":"30","key":"1803_CR51","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","volume":"33","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20\u2009+\u2009indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015;33(30):3467\u201374.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1803_CR52","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH van Oers","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, et al. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853\u20138.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1803_CR53","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/jnci\/djr418","volume":"103","author":"L Vidal","year":"2011","unstructured":"Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011;103(23):1799\u2013806.","journal-title":"J Natl Cancer Inst"},{"issue":"27","key":"1803_CR54","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26(27):4473\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1803_CR55","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","volume":"17","author":"M Rummel","year":"2016","unstructured":"Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57\u201366.","journal-title":"Lancet Oncol"},{"issue":"22","key":"1803_CR56","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","volume":"36","author":"BD Cheson","year":"2018","unstructured":"Cheson BD, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, et al. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J Clin Oncol. 2018;36(22):2259\u201366.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1803_CR57","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","volume":"122","author":"J Radford","year":"2013","unstructured":"Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122(7):1137\u201343.","journal-title":"Blood"},{"key":"1803_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022. https:\/\/doi.org\/10.1016\/S1470-2045(22)00335-7.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1803_CR59","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2024025454","volume":"145","author":"LH Sehn","year":"2025","unstructured":"Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u2265\u20092 prior therapies. Blood. 2025;145(7):708\u201319.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1803_CR60","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2022-159640","volume":"140","author":"SF McGough","year":"2022","unstructured":"McGough SF, Shamas N, Wang J, Jaber M, Swarup B, Blanchet Zumofen M-H, Lauti\u00e9 B, Parreira J, Wei MC, Shewade A. An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy. Blood. 2022;140(Supplement 1):3658\u201360.","journal-title":"Blood"},{"issue":"7","key":"1803_CR61","first-page":"2177","volume":"109","author":"MJ Maurer","year":"2024","unstructured":"Maurer MJ, Casulo C, Larson MC, Habermann TM, Lossos IS, Wang Y, et al. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma. Haematologica. 2024;109(7):2177\u201385.","journal-title":"Haematologica"},{"key":"1803_CR62","doi-asserted-by":"crossref","unstructured":"Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, Christensen JH, Hess B, Tilly H, Cordoba R et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol 2024.","DOI":"10.1016\/S2352-3026(24)00166-2"},{"issue":"Supplement 1","key":"1803_CR63","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1182\/blood-2024-200262","volume":"144","author":"L Falchi","year":"2024","unstructured":"Falchi L, Sureda Balari A, Lepp\u00e4 S, Vermaat JSP, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg P, et al. Fixed-Duration Epcoritamab\u2009+\u2009R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial. Blood. 2024;144(Supplement 1):342\u2013342.","journal-title":"Blood"},{"issue":"S1","key":"1803_CR64","first-page":"54","volume":"197","author":"KM Linton","year":"2022","unstructured":"Linton KM, Wahlin B, Lepp\u00e4 S, Morschhauser F, Elliott B, Liu T, et al. Subcutaneous epcoritamab in combination with rituximab and lenalidomide in relapsed or refractory follicular lymphoma: preliminary phase 1\/2 results. ALL, AML MDS & Bone Marrow Failure British Journal of Haematology. 2022;197(S1):54\u2013170.","journal-title":"ALL, AML MDS & Bone Marrow Failure British Journal of Haematology"},{"issue":"16suppl","key":"1803_CR65","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.1200\/JCO.2022.40.16_suppl.7524","volume":"40","author":"L Falchi","year":"2022","unstructured":"Falchi L, Lepp\u00e4 S, Wahlin BE, Nijland M, Christensen JH, Vos SD, Holte H, Linton KM, Abbas A, Wang L, et al. Subcutaneous epcoritamab with rituximab\u2009+\u2009lenalidomide (R\u2009<\u2009sup>2) in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): Update from phase 1\/2 trial. J Clin Oncol. 2022;40(16suppl):7524\u20137524.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1803_CR66","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1182\/blood-2024-200369","volume":"144","author":"J Brody","year":"2024","unstructured":"Brody J, Falchi L, Vitolo U, Nijland M, Offner F, Snauwaert S, Patah P, Marek J, Morehouse C, Steele AJ, et al. Fixed-Duration Epcoritamab in Combination with Bendamustine\u2009+\u2009Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3. Blood. 2024;144(Supplement 1):1627\u20131627.","journal-title":"Blood"},{"issue":"16suppl","key":"1803_CR67","doi-asserted-by":"publisher","first-page":"7014","DOI":"10.1200\/JCO.2024.42.16_suppl.7014","volume":"42","author":"LA Lori","year":"2024","unstructured":"Lori LA, Falchi L, Vermaat JSP, Musuraca G, Belada D, Nijland M, Christensen JH, Offner F, Hoehn D, Marek J, et al. Epcoritamab with rituximab\u2009+\u2009lenalidomide (R\u2009<\u2009sup>2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7. J Clin Oncol. 2024;42(16suppl):7014\u20137014.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1803_CR68","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1182\/blood-2023-180092","volume":"142","author":"L Falchi","year":"2023","unstructured":"Falchi L, Morschhauser F, Linton K, Huang H, Galderisi F, Quadri S, Zeng L, Hoehn D, Seymour JF. EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma. Blood. 2023;142(Supplement 1):3053\u20133053.","journal-title":"Blood"},{"issue":"16suppl","key":"1803_CR69","doi-asserted-by":"publisher","first-page":"TPS7084","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7084","volume":"42","author":"KM Linton","year":"2024","unstructured":"Linton KM, Thompson P, Luminari S, Casulo C, Patah P, Zeng L, Mei J, Dixit N, Hoehn D, Bachy E. EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R\u2009<\u2009sup>2) vs chemoimmunotherapy or R\u2009<\u2009sup>2\u2009in previously untreated follicular lymphoma. J Clin Oncol. 2024;42(16suppl):TPS7084\u20137084.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1803_CR70","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1182\/blood-2024-206520","volume":"144","author":"G von Keudell","year":"2024","unstructured":"von Keudell G, Logan EK, Redd RA, Leukam M, Weinstock M, Arnason JE, Advani RH. A Phase 2 Study of Epcoritamab in Patients with Follicular Lymphoma Not Achieveing a Complete Response with Front-Line Chemoimmunotherapy (EPCON). Blood. 2024;144(Supplement 1):6284\u20136284.","journal-title":"Blood"},{"issue":"24","key":"1803_CR71","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine. 2022;387(24):2220\u201331.","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"1803_CR72","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021;39(18):1959\u201370.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1803_CR73","doi-asserted-by":"publisher","first-page":"7020","DOI":"10.1200\/JCO.2024.42.16_suppl.7020","volume":"42","author":"NL Bartlett","year":"2024","unstructured":"Bartlett NL, Dickinson M, Hutchings M, Carlo-Stella C, Wu S-J, Lepp\u00e4 S, et al. Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R\/R) non-Hodgkin lymphoma (NHL): results from a phase I\/II study. J Clin Oncol. 2024;42(16_suppl):7020\u20137020.","journal-title":"J Clin Oncol"},{"key":"1803_CR74","unstructured":"Multicenter A. Open-label, Phase I\/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva\u00ae\/Gazyvaro\u2122) in Patients With Relapsed\/Refractory B-cell Non-hodgkin\u2019s Lymphoma. In.; 2017."},{"issue":"Supplement 1","key":"1803_CR75","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood-2021-148778","volume":"138","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Carlo-Stella C, Dickinson M, Phillips T, Houot R, Offner F, Haioun C, Corradini P, Hutchings M, Sureda A, et al. Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R\/R) Follicular Lymphoma (FL). Blood. 2021;138(Supplement 1):128\u2013128.","journal-title":"Blood"},{"issue":"5","key":"1803_CR76","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","volume":"9","author":"R Bannerji","year":"2022","unstructured":"Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, et al. Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9(5):e327\u201339.","journal-title":"Lancet Haematol"},{"issue":"11","key":"1803_CR77","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","volume":"35","author":"TM Kim","year":"2024","unstructured":"Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, et al. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma\u2606. Ann Oncol. 2024;35(11):1039\u201347.","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"1803_CR78","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1182\/blood-2023-181650","volume":"142","author":"JC Villasboas","year":"2023","unstructured":"Villasboas JC, Kim TM, Taszner M, Novelli S, Cho S-G, Merli M, Jimenez Ubieto A, Tessoulin B, Poon M, Walewski J, et al. Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed\/Refractory (R\/R) Follicular Lymphoma (FL) with Extended Follow-up. Blood. 2023;142(Supplement 1):3041\u20133041.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1803_CR79","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood-2024-199100","volume":"144","author":"S Luminari","year":"2024","unstructured":"Luminari S, Villasboas Bisneto JC, Chong G, Tucker D, Ambati S, Lin C, Mohamed H, Otele CA, Antico G, Jim\u00e9nez Ubieto A. Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study. Blood. 2024;144(Supplement 1):1628\u20131628.","journal-title":"Blood"},{"issue":"16_suppl","key":"1803_CR80","doi-asserted-by":"publisher","first-page":"7076","DOI":"10.1200\/JCO.2024.42.16_suppl.7076","volume":"42","author":"S Luminari","year":"2024","unstructured":"Luminari S, Harnett J, Thieblemont C, Prochazka K, Townsend W, Radford J, et al. Results from the follicular lymphoma (FL) outcomes in patients (pts) with relapsed\/refractory (R\/R) disease treated with systemic therapy in a real-world assessment (FLORA) study. J Clin Oncol. 2024;42(16_suppl):7076\u20137076.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1803_CR81","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1182\/blood-2024-200080","volume":"144","author":"E Brem","year":"2024","unstructured":"Brem E, Jurczak W, Belada D, Perez de Oteyza J, Alonso AA, Altuntas F, Kwiatek M, Brody J, Perez Persona E, Yenerel M, et al. Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study. Blood. 2024;144(Supplement 1):4411\u20134411.","journal-title":"Blood"},{"issue":"16_suppl","key":"1803_CR82","doi-asserted-by":"publisher","first-page":"TPS7094","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7094","volume":"42","author":"U Vitolo","year":"2024","unstructured":"Vitolo U, Merli M, Norasetthada L, Wassenaar TR, Mart\u00edn EMD, Bobillo S, et al. Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed\/refractory (R\/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5). J Clin Oncol. 2024;42(16_suppl):TPS7094\u2013TPS7094.","journal-title":"J Clin Oncol"},{"key":"1803_CR83","doi-asserted-by":"crossref","unstructured":"Fonseca R, Liu AJ, Langlais BT, Almader-Douglas D, Vikram HR, Hilal T. Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis. Blood Neoplasia 2025, 2(1).","DOI":"10.1016\/j.bneo.2024.100061"},{"issue":"16_suppl","key":"1803_CR84","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.1200\/JCO.2023.41.16_suppl.7524","volume":"41","author":"R Nair","year":"2023","unstructured":"Nair R, Jacobs R, Cho S-G, Devata S, Gaballa S, Yoon DH, et al. High complete response rate with TNB-486 in relapsed\/refractory follicular lymphoma: interim results from an ongoing phase 1 study. J Clin Oncol. 2023;41(16_suppl):7524\u20137524.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1803_CR85","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1182\/blood-2021-153355","volume":"138","author":"E Budde","year":"2021","unstructured":"Budde E, Gopal AK, Kim WS, Flinn IW, Cheah CYY, Nastoupil L, Matasar MJ, Diefenbach CS, Gregory GP, Qazi I, et al. A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. Blood. 2021;138(Supplement 1):132\u2013132.","journal-title":"Blood"},{"issue":"1","key":"1803_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01646-2","volume":"17","author":"J Yang","year":"2024","unstructured":"Yang J, Song Y, Zhou K, Li Z, Zhang M, Jing H, et al. Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRP\u03b1, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1\/2 study. J Hematol Oncol. 2024;17(1):123.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1803_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1803_CR88","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91\u2013103.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"1803_CR89","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1182\/blood-2024-194627","volume":"144","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, et al. 5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma. Blood. 2024;144(Supplement 1):864\u2013864.","journal-title":"Blood"},{"issue":"16_suppl","key":"1803_CR90","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1200\/JCO.2023.41.16_suppl.7509","volume":"41","author":"CA Jacobson","year":"2023","unstructured":"Jacobson CA, Hemmer MT, Hu Z-H, Frank MJ, Popplewell L, Ahmed N, et al. Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R\/R) follicular lymphoma (FL). J Clin Oncol. 2023;41(16_suppl):7509\u20137509.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1803_CR91","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332.","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"1803_CR92","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1182\/blood-2024-201730","volume":"144","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont C, Dreyling M, Dickinson MJ, Mart\u00ednez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell LL, Chavez JC, Bachy E, et al. Clinical Outcomes of Patients with High-Risk Relapsed\/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update. Blood. 2024;144(Supplement 1):3034\u20133034.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1803_CR93","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2023-184653","volume":"142","author":"L Ysebaert","year":"2023","unstructured":"Ysebaert L, Houot R, Casasnovas O, Sylvain C, Jardin F, Loschi M, Brisou G, Thieblemont C, Bay J-O, Castilla-Llorente C, et al. Real-Word Experience of CAR T-Cells in Patients with Relapsed\/Refractory Follicular Lymphoma: A Descart Registry Analysis from the Lysa. Blood. 2023;142(Supplement 1):296\u2013296.","journal-title":"Blood"},{"key":"1803_CR94","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1182\/blood-2024-204207","volume":"144","author":"DJ Landsburg","year":"2024","unstructured":"Landsburg DJ, Maziarz RT, Moskop A, Popplewell LL, Solomon SR, Tees MT, et al. Efficacy and safety of tisagenlecleucel in patients with relapsed\/refractory follicular lymphoma: a real-world analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) registry. Blood. 2024;144:4398.","journal-title":"Blood"},{"issue":"8","key":"1803_CR95","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024;30(8):2199\u2013207.","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"1803_CR96","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2024-198509","volume":"144","author":"L Nastoupil","year":"2024","unstructured":"Nastoupil L, Dahiya S, Palomba ML, Mart\u00edn Garc\u00eda-Sancho A, Reguera JL, Kuruvilla J, Jaeger U, Cartron G, Izutsu K, Dreyling M, et al. Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R\/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up. Blood. 2024;144(Supplement 1):4387\u20134387.","journal-title":"Blood"},{"issue":"16_suppl","key":"1803_CR97","doi-asserted-by":"publisher","first-page":"TPS7579","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7579","volume":"41","author":"IW Flinn","year":"2023","unstructured":"Flinn IW, Jacobson CA, Nastoupil LJ, Morschhauser F, Davies A, Buske C, et al. ZUMA-22: a phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R\/R) follicular lymphoma (FL). J Clin Oncol. 2023;41(16_suppl):TPS7579\u2013TPS7579.","journal-title":"J Clin Oncol"},{"key":"1803_CR98","unstructured":"A Global Randomized Multicenter. Phase 3 Trial to Compare the Efficacy and Safety of Lisocabtagene Maraleucel (JCAR017\/BMS-986387) to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (TRANSFORM FL). In. Edited by Celgene C; 2024."},{"issue":"Supplement 1","key":"1803_CR99","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1182\/blood-2023-178629","volume":"142","author":"S Kambhampati","year":"2023","unstructured":"Kambhampati S, Wang H-L, Yan J, Herrera AF, Frank MJ, Popplewell LL, Ahmed N, Lin Y, Locke FL, Ghione P, et al. Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data. Blood. 2023;142(Supplement 1):2121\u20132121.","journal-title":"Blood"},{"issue":"3","key":"1803_CR100","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3324\/haematol.2022.281421","volume":"108","author":"P Ghione","year":"2022","unstructured":"Ghione P, Palomba ML, Ghesquieres H, Bobillo S, Patel AR, Nahas M, et al. Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica. 2022;108(3):822\u201332.","journal-title":"Haematologica"},{"issue":"7","key":"1803_CR101","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0173","volume":"12","author":"Y Hao","year":"2023","unstructured":"Hao Y, Hsu WC, Parzynski CS, Degtyarev E, Hampson LV, Masood A, et al. Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed\/refractory follicular lymphoma. J Comp Eff Res. 2023;12(7):e220173.","journal-title":"J Comp Eff Res"},{"issue":"7","key":"1803_CR102","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386(7):629\u201339.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"1803_CR103","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2024-203753","volume":"144","author":"J Sharp","year":"2024","unstructured":"Sharp J, Strati P, Bhatta S, Huang JJ, Thomas C, Reef DK, Gorzewski A, Reinert C, Teferra A, Pelcovits A, et al. Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R\/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers. Blood. 2024;144(Supplement 1):2377\u20132377.","journal-title":"Blood"},{"issue":"5","key":"1803_CR104","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s10637-023-01389-w","volume":"41","author":"B Ghanem","year":"2023","unstructured":"Ghanem B. Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma. Invest New Drugs. 2023;41(5):710\u20138.","journal-title":"Invest New Drugs"},{"issue":"1","key":"1803_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00610-1","volume":"14","author":"LJ Nastoupil","year":"2025","unstructured":"Nastoupil LJ, Bonner A, Wang P, Almuallem L, Desai J, Farazi T, et al. Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma. Exp Hematol Oncol. 2025;14(1):30.","journal-title":"Exp Hematol Oncol"},{"issue":"16_suppl","key":"1803_CR106","doi-asserted-by":"publisher","first-page":"7068","DOI":"10.1200\/JCO.2024.42.16_suppl.7068","volume":"42","author":"JL Reguera","year":"2024","unstructured":"Reguera JL, Garcia-Sancho AM, Kuruvilla J, Izutsu K, Barbui AM, Peter B, et al. Impact of bridging therapy (BT) on lisocabtagene maraleucel (liso-cel) treatment in patients (pt) with R\/R follicular lymphoma (FL). J Clin Oncol. 2024;42(16_suppl):7068\u20137068.","journal-title":"J Clin Oncol"},{"key":"1803_CR107","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.radonc.2022.10.018","volume":"177","author":"Q Yu","year":"2022","unstructured":"Yu Q, Zhang X, Wang N, Li C, Zhang Y, Zhou J, et al. Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed\/refractory aggressive B-cell lymphoma. Radiother Oncol. 2022;177:53\u201360.","journal-title":"Radiother Oncol"},{"issue":"2","key":"1803_CR108","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, Navarro V, Mart\u00edn-L\u00f3pez A, Rejeski K, Kwon M, Jalowiec KA, et al. Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. J Clin Oncol. 2024;42(2):205\u201317.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1803_CR109","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","volume":"122","author":"C B\u00f6d\u00f6r","year":"2013","unstructured":"B\u00f6d\u00f6r C, Grossmann V, Popov N, Okosun J, O\u2019Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122(18):3165\u20138.","journal-title":"Blood"},{"issue":"2","key":"1803_CR110","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/ng.518","volume":"42","author":"RD Morin","year":"2010","unstructured":"Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181\u20135.","journal-title":"Nat Genet"},{"issue":"5","key":"1803_CR111","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","volume":"23","author":"W B\u00e9guelin","year":"2013","unstructured":"B\u00e9guelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677\u201392.","journal-title":"Cancer Cell"},{"issue":"4","key":"1803_CR112","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1038\/bcj.2017.32","volume":"7","author":"S Huet","year":"2017","unstructured":"Huet S, Xerri L, Tesson B, Mareschal S, Taix S, Mescam-Mancini L, et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J. 2017;7(4):e555\u2013e555.","journal-title":"Blood Cancer J"},{"issue":"11","key":"1803_CR113","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433\u201342.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1803_CR114","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1111\/cas.15040","volume":"112","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Ando K, Nishikori M, Shibayama H, Teshima T, Kuroda J, et al. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci. 2021;112(9):3627\u201335.","journal-title":"Cancer Sci"},{"issue":"Supplement 1","key":"1803_CR115","doi-asserted-by":"publisher","first-page":"6347","DOI":"10.1182\/blood-2024-208702","volume":"144","author":"G Salles","year":"2024","unstructured":"Salles G, Leonard JP, Morschhauser F, Crowley A, Sosinsky AZ, Lieb C, Zeldow B, Harton J, Wang S, Boyer J, et al. Comparison of Progression-Free Survival of Relapsed or Refractory Follicular Lymphoma Patients in a Single-Arm Trial of Tazemetostat with a Real-World External Control Arm. Blood. 2024;144(Supplement 1):6347\u20136347.","journal-title":"Blood"},{"key":"1803_CR116","doi-asserted-by":"publisher","first-page":"677","DOI":"10.18632\/oncotarget.28229","volume":"13","author":"DG Proudman","year":"2022","unstructured":"Proudman DG, Gupta D, Nellesen D, Yang J, Kamp BA, Mamlouk K, et al. Tazemetostat in relapsed\/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes. Oncotarget. 2022;13:677\u201383.","journal-title":"Oncotarget"},{"issue":"Supplement 1","key":"1803_CR117","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1182\/blood-2022-166991","volume":"140","author":"CL Batlevi","year":"2022","unstructured":"Batlevi CL, Salles G, Park SI, Phillips TJ, Amengual JE, Andorsky D, Campbell P, McKay P, Leonard JP, Sondhi M, et al. Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed\/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1. Blood. 2022;140(Supplement 1):2296\u20138.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1803_CR118","doi-asserted-by":"publisher","first-page":"7759","DOI":"10.1182\/blood-2024-203752","volume":"144","author":"S Dennen","year":"2024","unstructured":"Dennen S, Dillon A, Cockrum P, Kambhampati S. Hematologic Toxicity Among Real-World US Patients with Follicular Lymphoma Treated with Tazemetostat Compared to Other Standard-of-Care Therapies. Blood. 2024;144(Supplement 1):7759\u20137759.","journal-title":"Blood"},{"issue":"33","key":"1803_CR119","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1200\/JCO.23.00775","volume":"41","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, Mayer J, Flowers CR, Bijou F, Oliveira ACD, Song Y, et al. ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol. 2023;41(33):5107\u201317.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1803_CR120","doi-asserted-by":"publisher","first-page":"TPS7590","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7590","volume":"41","author":"LJ Nastoupil","year":"2023","unstructured":"Nastoupil LJ, Song Y, Sehn LH, Sarkozy C, Zinzani PL, Silvestre AS, et al. MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma. J Clin Oncol. 2023;41(16_suppl):TPS7590\u2013TPS7590.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1803_CR121","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","volume":"131","author":"NL Bartlett","year":"2018","unstructured":"Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018;131(2):182\u201390.","journal-title":"Blood"},{"issue":"4","key":"1803_CR122","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjh.16424","volume":"189","author":"NH Fowler","year":"2020","unstructured":"Fowler NH, Nastoupil L, De Vos S, Knapp M, Flinn IW, Chen R, et al. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. Br J Haematol. 2020;189(4):650\u201360.","journal-title":"Br J Haematol"},{"key":"1803_CR123","doi-asserted-by":"crossref","unstructured":"Ujjani C, Wang H, Broome C, Gopal AK, Smith SD, Lai C, Shadman M, Leslie L, Warren EH, Lynch R et al. Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 2025.","DOI":"10.2139\/ssrn.5173096"},{"issue":"S2","key":"1803_CR124","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/hon.3163_80","volume":"41","author":"B \u00d8stenstad","year":"2023","unstructured":"\u00d8stenstad B, Pirosa MC, Sch\u00e4r S, Brodtkorb M, Wahlin BE, Hernberg M, et al. SAKK 35\/14 randomized trial of rituximab with or without ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. Hematol Oncol. 2023;41(S2):117\u20139.","journal-title":"Hematol Oncol"},{"issue":"22","key":"1803_CR125","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1182\/bloodadvances.2023010298","volume":"7","author":"LJ Nastoupil","year":"2023","unstructured":"Nastoupil LJ, Hess G, Pavlovsky MA, Danielewicz I, Freeman J, Garc\u00eda-Sancho AM, et al. Phase 3 SELENE study: ibrutinib plus BR\/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 2023;7(22):7141\u201350.","journal-title":"Blood Adv"},{"issue":"3","key":"1803_CR126","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/bjh.19951","volume":"206","author":"P Strati","year":"2025","unstructured":"Strati P, Agajanian R, Lossos IS, Coleman M, Kridel R, Wood A, et al. Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: results of the phase 1b open-label study (ACE-LY-003). Br J Haematol. 2025;206(3):887\u201398.","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"1803_CR127","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1182\/blood-2023-181309","volume":"142","author":"NN Shah","year":"2023","unstructured":"Shah NN, Zinzani PL, Wang ML, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, et al. Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed\/Refractory Follicular Lymphoma: Results from the Phase 1\/2 BRUIN Study. Blood. 2023;142(Supplement 1):3026\u20133026.","journal-title":"Blood"},{"issue":"19","key":"1803_CR128","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","volume":"137","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O\u2019Connor OA, Feingold JM, Ardeshna KM, Townsend W, Solh M, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634\u201345.","journal-title":"Blood"},{"key":"1803_CR129","doi-asserted-by":"crossref","unstructured":"Alderuccio JP, Alencar AJ, Schatz JH, Kuker RA, Pongas G, Reis IM, Lekakis LJ, Spiegel JY, Sandoval-Sus J, Beitinjaneh A et al. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial. Lancet Haematol 2024.","DOI":"10.1016\/S2352-3026(24)00345-4"},{"issue":"5","key":"1803_CR130","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","volume":"113","author":"E Gyan","year":"2009","unstructured":"Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood. 2009;113(5):995\u20131001.","journal-title":"Blood"},{"issue":"2","key":"1803_CR131","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/bjh.18640","volume":"201","author":"R Puckrin","year":"2023","unstructured":"Puckrin R, Chua N, Chin K, Peters A, Duggan P, Shafey M, et al. Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma. Br J Haematol. 2023;201(2):319\u201325.","journal-title":"Br J Haematol"},{"issue":"1","key":"1803_CR132","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/jnci\/djr450","volume":"104","author":"M Al Khabori","year":"2012","unstructured":"Al Khabori M, de Almeida JR, Guyatt GH, Kuruvilla J, Crump M. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(1):18\u201328.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"1803_CR133","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/cncr.31374","volume":"124","author":"SM Smith","year":"2018","unstructured":"Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, et al. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018;124(12):2541\u201351.","journal-title":"Cancer"},{"issue":"3","key":"1803_CR134","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2021.280287","volume":"108","author":"TA Eyre","year":"2022","unstructured":"Eyre TA, Barrington SF, Okosun J, Abamba C, Pearce RM, Lee J, et al. Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation. Haematologica. 2022;108(3):785\u201396.","journal-title":"Haematologica"},{"issue":"20","key":"1803_CR135","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1002\/cncr.28243","volume":"119","author":"AM Evens","year":"2013","unstructured":"Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, et al. Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer. 2013;119(20):3662\u201371.","journal-title":"Cancer"},{"issue":"11","key":"1803_CR136","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.3109\/10428194.2011.594925","volume":"52","author":"AC Peters","year":"2011","unstructured":"Peters AC, Duan Q, Russell JA, Duggan P, Owen C, Stewart DA. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. Leuk Lymphoma. 2011;52(11):2124\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1803_CR137","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231221012","volume":"52","author":"A Kenyeres","year":"2024","unstructured":"Kenyeres A, Kiss E, Simon Z, Ill\u00e9s \u00c1, J\u00f3na \u00c1. Age and lymphocyte\/monocyte ratio as prognostic factors for autologous transplantation in the treatment of patients with follicular lymphoma. J Int Med Res. 2024;52(2):3000605231221012.","journal-title":"J Int Med Res"},{"key":"1803_CR138","doi-asserted-by":"crossref","unstructured":"Ghosh N, Bellasea S, Li H, Olszewski AJ, Bryan L, Danilov A, Smith S, LeBlanc M, Friedberg JW. SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low\u2013Tumor Burden Follicular Lymphoma. JCO Oncol Adv 2025(2):e2500037.","DOI":"10.1200\/OA-25-00037"},{"key":"1803_CR139","doi-asserted-by":"crossref","unstructured":"Ioannou N, Jain K, Ramsay AG. Immunomodulatory Drugs for the Treatment of B Cell Malignancies. Int J Mol Sci 2021, 22(16).","DOI":"10.3390\/ijms22168572"},{"key":"1803_CR140","doi-asserted-by":"publisher","first-page":"S835","DOI":"10.1016\/S2152-2650(25)02442-5","volume":"25","author":"R Cordoba","year":"2025","unstructured":"Cordoba R, Chavez J, Perini GF, Nastoupil L, J\u00f8rgensen JM, Bories P, et al. IBCL-1109: golcadomide, a CELMoD agent, with or without rituximab in patients with relapsed\/refractory follicular lymphoma (R\/R FL): updated phase 1\/2 results. Clin Lymphoma Myeloma Leuk. 2025;25:S835\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16_suppl","key":"1803_CR141","doi-asserted-by":"publisher","first-page":"TPS7092","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7092","volume":"42","author":"G Chong","year":"2024","unstructured":"Chong G, Palmer J, Barraclough A, Churilov L, Keane C, Lee ST, et al. First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +\/- nivolumab: an umbrella randomised phase 2 investigator-led study. J Clin Oncol. 2024;42(16_suppl):TPS7092\u2013TPS7092.","journal-title":"J Clin Oncol"},{"key":"1803_CR142","doi-asserted-by":"crossref","unstructured":"Villasboas Bisneto JC, Zinzani PL, Davies AJ, Kridel R, Perini GF, Rao P, Mikita-Geoffroy J, Sudhindra A, Andreadis C. Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma. Blood 2024, 144(Supplement 1):4422.4422-4422.4422.","DOI":"10.1182\/blood-2024-203181"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01803-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01803-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01803-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:20:27Z","timestamp":1785522027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01803-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":142,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1803"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01803-5","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"77"}}